FDA Panel Unanimously Endorses Moderna COVID Boosters for At-Risk Adults

A healthcare worker holds a vial of the Moderna COVID-19 vaccine at a pop-up vaccination site in New York City, January 29, 2021. (Mike Segar/Reuters)

A Food and Drug Administration advisory committee on Thursday unanimously endorsed booster shots of Moderna’s COVID-19 vaccine for those who are at high risk of severe COVID-19, occupational exposure to COVID-19 or are 65 years and older.

The FDA’s Vaccines and Related Biological Products Advisory Committee endorsed a half-dose as a third injection, at least six months after receiving a second dose.  The agency is not required to follow the panel’s recommendation, though it typically does.

An FDA decision could come within days. If the FDA chooses to accept the advice, the CDC vaccine advisory committee would then vote on the FDA’s proposal.

If the shots are approved, it would bring guidance for Moderna shots in line with Pfizer’s COVID-19 vaccine, which was approved for booster shots for the same groups of Americans less than a month ago.

#inline-newsletter-nloptin-6168ac6b13522 .inline-newsletter-subscribe__cta label { font-size: 1.2rem; line-height: 1.5rem; color: #000000; } #inline-newsletter-nloptin-6168ac6b13522 .inline-newsletter-subscribe__cta p { font-size: 1.05rem; line-height: 1.45rem; color: #000000; } #inline-newsletter-nloptin-6168ac6b13522 { background-color: #ffffff; border-width: 1px; border-color: #cccccc;

View Source